<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00533039</url>
  </required_header>
  <id_info>
    <org_study_id>SPIDER001</org_study_id>
    <secondary_id>A Sub-study of SPIDER-PCI</secondary_id>
    <nct_id>NCT00533039</nct_id>
  </id_info>
  <brief_title>sPLA2 Inhibition to Decrease Enzyme Release After PCI Trial</brief_title>
  <acronym>SPIDER-PCI</acronym>
  <official_title>sPLA2 Inhibition to Decrease Enzyme Release After PCI (SPIDER-PCI) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anthera Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As evidence accumulates that atherogenesis or Coronary Artery Disease (CAD) may not be simply&#xD;
      a disorder of lipid metabolism, but an inflammatory disease, the focus of treatment has&#xD;
      shifted. A-002 or Varespladib is an anti-inflammatory drug for treatment of chronic and acute&#xD;
      diseases. It acts by inhibiting secretory phospholipase A2 (sPLA2 ) - one of a family of&#xD;
      enzymes leading to inflammation - which may be important in: 1) the development of&#xD;
      atherosclerosis and 2) the increase in occurence of cardiovascular events after angioplasty.&#xD;
      Previous studies have demonstrated that sPLA2: 1) facilitates the pro-atherogenic effects of&#xD;
      low-density (LDL or bad cholesterol) and 2) increased levels post-angioplasty correlate with&#xD;
      an increased risk of events at followup contact. Therefore this study proposes to investigate&#xD;
      the ability of A-002 to prevent or reduce myocardial damage after angioplasty by inhibiting&#xD;
      the cascade of inflammatory mediators.&#xD;
&#xD;
      Substudy - Subjects who agree will also have a vascular ultrasound 24h post-PCI to assess&#xD;
      endothelial function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tissue injury after angioplasty is likely due to micro-emboli from mechanical trauma to a&#xD;
      thrombotic lesion during angioplasty. In response to the ischemia sPLA2, possibly localized&#xD;
      within atherosclerotic vascular tissue as well as from macrophages and monocytes, is&#xD;
      released. Following ischemia-induced release, sPLA2 can bind to ischemically challenged&#xD;
      cardiomyocytes and adversely affect their survival either directly through toxic effects on&#xD;
      cardiomyocytes or indirectly by facilitating inflammation. It may be possible through sPLA2&#xD;
      inhibition to salvage non-lethally jeopardized cells following an ischemic episode thereby&#xD;
      reducing the infarcted area and amount of tissue damage. Previous studies in patients with&#xD;
      unstable angina support this hypothesis, and conclude that sPLA2 levels can be used to&#xD;
      predict clinical outcomes. We hypothesize that sPLA2 inhibition with A-002 will reduce&#xD;
      myocardial injury post-angioplasty.&#xD;
&#xD;
      Substudy - Peripheral vascular ultrasound should be done prior to receiving study drug and&#xD;
      24h post-PCI. Coronary endothelial function will be assessed at the time of PCI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint will be incidence of myocardial injury as evidenced by elevation of CK-MB or troponin I above the upper limit of normal.</measure>
    <time_frame>8 hours and 18-24 hours post-angioplasty</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>A secondary endpoint will be occurrence of elevation of CK-MB or troponin I above the upper limit of normal.</measure>
    <time_frame>8 and 18-24 hours post-angioplasty</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A secondary endpoint will be occurrence of any major adverse cardiac events (MACE).</measure>
    <time_frame>30 days post-angioplasty</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A secondary outcome will be serum sPLA2 activity.</measure>
    <time_frame>5-7 days post-angioplasty</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects take 2 tablets BID. Placebo tablets are identical to active medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Varespladib (A-002)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects take 250mg tablets BID beginning 3-5 days pre-angioplasty and for 5 days post-angioplasty.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varespladib (A-002)</intervention_name>
    <description>250mg tablets BID for 3-5 days pre-angioplasty and 5 days post-angioplasty.</description>
    <arm_group_label>Varespladib (A-002)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>250mg tablets BID 3-5 days pre-angioplasty and 5 days post-angioplasty.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women ≥ 18 years of age undergoing elective PCI, with or without stenting&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ST elevation MI or any troponin elevation (non-STEMI) within preceding 10days&#xD;
&#xD;
          -  Elevation of CK-MB or troponin I at baseline&#xD;
&#xD;
          -  Recent (4 weeks) coronary bypass surgery&#xD;
&#xD;
          -  NYHA class III-IV heart failure&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 0.30&#xD;
&#xD;
          -  Severe valvular heart disease&#xD;
&#xD;
          -  Chronic inflammatory disease (e.g., lupus, rheumatoid arthritis, inflammatory bowel&#xD;
             disease), or patients receiving steroid drugs&#xD;
&#xD;
          -  Presence of severe liver disease with cirrhosis&#xD;
&#xD;
          -  Recent active hepatitis&#xD;
&#xD;
          -  Active chronic hepatitis&#xD;
&#xD;
          -  ALT or AST &gt; 3 × upper limit of normal (ULN)&#xD;
&#xD;
          -  Biliary obstruction with hyperbilirubinemia (total bilirubin &gt; 2 × ULN)&#xD;
&#xD;
          -  Moderate or severe renal impairment (creatinine &gt; 1.5 × ULN)&#xD;
&#xD;
          -  Nephrotic syndrome or subjects undergoing dialysis&#xD;
&#xD;
          -  Uncontrolled diabetes (HbA1c &gt; 11% 1 month prior to screening)&#xD;
&#xD;
          -  Initiation of statin therapy within 30 days&#xD;
&#xD;
          -  Inability to provide consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir Dzavik, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <study_first_submitted>September 19, 2007</study_first_submitted>
  <study_first_submitted_qc>September 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2007</study_first_posted>
  <last_update_submitted>October 8, 2009</last_update_submitted>
  <last_update_submitted_qc>October 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Vladimir Dzavik, MD</name_title>
    <organization>University Health Network</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varespladib methyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

